LOS ANGELES, CA / ACCESSWIRE / July 8, 2016 / Lundin Law PC announces that a class action lawsuit has been filed against NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ: NLNK) concerning possible violations of federal securities laws between September 17, 2013 and May 9, 2016 (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 11, 2016 lead plaintiff motion deadline.
To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at [email protected].
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the complaint, the Company made false and/or misleading statements during the Class Period touting the effectiveness of the Company's algenpantucel-L pancreatic cancer treatment. On May 9, 2016 the Company announced that the treatment failed to meet its primary endpoint and according to the Phase 3 Clinical Trial, patients treated with algenpantucel-L survived for a median of 27.3 months while patients treated with standard therapy survived 30.4 months. When this news was released, NewLink's stock price fell about 30.61%, causing investors harm.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
lundinlawpc.com
SOURCE: Lundin Law PC